407 related articles for article (PubMed ID: 22428857)
1. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
2. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
3. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
Maeda H; Kurokawa T
Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
[TBL] [Abstract][Full Text] [Related]
4. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
5. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers.
Yamashita K; Kaneko M; Narukawa M
Clin Pharmacol Ther; 2019 Jan; 105(1):153-160. PubMed ID: 29882302
[TBL] [Abstract][Full Text] [Related]
6. [Consideration of clinical development for new anticancer drugs on Japan, proposal from approval reviewer].
Urano T
Gan To Kagaku Ryoho; 2007 Feb; 34(2):305-7. PubMed ID: 17301550
[TBL] [Abstract][Full Text] [Related]
7. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
[TBL] [Abstract][Full Text] [Related]
8. Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study.
Maeda H; Hara A; Ofuchi M; Shingai R; Misumi T; Murai Y
Clin Transl Sci; 2023 Dec; 16(12):2665-2674. PubMed ID: 37815272
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the success rates of new drug development in Japan and the lag behind the US.
Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
[TBL] [Abstract][Full Text] [Related]
10. Oncology drug lag in Japan: has it improved over the last decade?
Tachibana Y; Narukawa M
Int J Clin Oncol; 2023 Nov; 28(11):1451-1460. PubMed ID: 37561368
[TBL] [Abstract][Full Text] [Related]
11. Relationship between drug lag and factors associated with clinical trials in Japan.
Ohwaki K; Nakabayashi T
J Clin Pharm Ther; 2014 Dec; 39(6):649-52. PubMed ID: 25200123
[TBL] [Abstract][Full Text] [Related]
12. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
13. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
Maeda H; Kurokawa T
J Clin Pharmacol; 2015 May; 55(5):481-9. PubMed ID: 25560978
[TBL] [Abstract][Full Text] [Related]
14. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
Tsuji K; Tsutani K
Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
[TBL] [Abstract][Full Text] [Related]
15. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.
Maeda H; Kurokawa T
Invest New Drugs; 2014 Aug; 32(4):661-9. PubMed ID: 24615632
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic indications in oncology: emerging features and regulatory dynamics.
Tafuri G; Leufkens HG; Laing R; Trotta F
Eur J Cancer; 2010 Feb; 46(3):471-5. PubMed ID: 20056536
[TBL] [Abstract][Full Text] [Related]
18. Delays in new drug applications in Japan and industrial R&D strategies.
Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
[TBL] [Abstract][Full Text] [Related]
19. The notorious "drug lag" for oncology drugs in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
[TBL] [Abstract][Full Text] [Related]
20. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
Maki A; Narukawa M
Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]